News
AMRX
6.76
+8.86%
0.55
Amneal Pharmaceuticals Price Target Raised to $9.00/Share From $7.00 by Truist Securities
Dow Jones · 13m ago
Truist Securities Reiterates Buy on Amneal Pharmaceuticals, Raises Price Target to $9
Benzinga · 23m ago
Amneal Pharmaceuticals (AMRX) Receives a Buy from Piper Sandler
TipRanks · 26m ago
AMNEAL PHARMA <AMRX.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $9 FROM $7
Reuters · 1h ago
Weekly Report: what happened at AMRX last week (0429-0503)?
Weekly Report · 3h ago
Barclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
TipRanks · 4h ago
Amneal Pharmaceuticals: A Strong Buy on Robust Growth and Promising Pipeline
Goldman Sachs analyst Nathan Rich has maintained their bullish stance on Amneal Pharmaceuticals stock. The company's first-quarter sales exceeded expectations. Truist Financial also maintained a Buy rating on the stock with a $9.00 price target on May 3. Nathan Rich believes the company has a strong potential for growth.
TipRanks · 13h ago
Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)
Amneal Pharmaceuticals's revenue is forecast to grow 4.5% p.a. On average in the next 3 years. The company's shares are up 15% from a week ago. Revenue for the first quarter of 2024 is expected to be up 18% to US$659.2m.
Simply Wall St · 2d ago
Amneal stock climbs on Q1 report, opioid settlement update
Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) climbed 9% Friday after the drugmaker released a better-than-expected Q1 earnings report. The company said it has reached an agreement in principle to settle litigation filed against the company over its alleged role in the US opioid crisis. Under the settlement, the company would pay $92.5M in cash and provide $180M in naloxone nasal spray.
Seeking Alpha · 2d ago
Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement
Amneal Pharmaceuticals Inc has agreed to pay $270 million to settle claims related to its alleged contribution to the opioid crisis in the U.S. The company will pay $92.5 million in cash and provide $180 million worth of naloxone nasal spray. Amneal is the latest pharmaceutical company to settle lawsuits related to the addiction epidemic.
Benzinga · 2d ago
Amneal Pharmaceuticals: A Strong Buy on Robust Q1 Performance and Promising IPX-203 Launch
TipRanks · 2d ago
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Amneal Pharmaceuticals reported earnings per share of 14 cents for the first quarter of 2024. The company reported revenue of $659.19 million. This was 6.49% better than the analyst estimate of $619.03 million. Amneal pharmaceuticals just reported results for first quarter 2024.
Investorplace · 2d ago
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
Drugmaker Amneal Pharmaceuticals agrees to $270 million U.S. Opioid settlement. The company is the latest to settle lawsuits over the addiction crisis brought by states and local governments. New Jersey-based company says it will pay $92.5 million in cash and provide $180 million in spray.
Reuters · 2d ago
Amneal Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Amneal Pharmaceuticals Inc reported quarterly adjusted earnings of 14 cents per share for the quarter ended in March. The company reported a quarterly loss of $91.64 million. Revenue rose 18.2% to $659.19 million from the same quarter last year.
Reuters · 2d ago
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
NASDAQ · 2d ago
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
NASDAQ · 3d ago
*Amneal Pharmaceuticals Sees 2024 Rev $2.55B-$2.65B >AMRX
Dow Jones · 3d ago
Amneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $659M beats by $39.97M
Amneal Pharmaceuticals reports Q1 earnings of $0.14, revenue of $659M beats by $39.97M. The company is affirming its full year 2024 guidance of $2.55B to $3B. The stock is down 2.7% in the last day of trading.
Seeking Alpha · 3d ago
*Amneal Pharmaceuticals 1Q Rev $659.2M >AMRX
Dow Jones · 3d ago
*Amneal Pharmaceuticals 1Q Adj EPS 14c >AMRX
Dow Jones · 3d ago
More
Webull provides a variety of real-time AMRX stock news. You can receive the latest news about Amneal Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMRX
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.